Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders

被引:29
作者
Bittencourt, H [1 ]
Rocha, V [1 ]
Filion, A [1 ]
Ionescu, I [1 ]
Herr, AL [1 ]
Garnier, F [1 ]
Ades, L [1 ]
Esperou, H [1 ]
Devergie, A [1 ]
Ribaud, P [1 ]
Socie, G [1 ]
Gluckman, E [1 ]
机构
[1] Hop St Louis, Serv Hematol Greffe de Moelle, Bone Marrow Transplant Unit, F-75475 Paris, France
关键词
poor graft function; allogeneic bone marrow transplant; hematopoietic growth factors;
D O I
10.1038/sj.bmt.1705072
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Poor graft function (PGF) is a frequent cause of morbidity after allogeneic hematopoietic stem cell transplantation (allo-HSCT). To study the value of granulocyte colony-stimulating factor (G-CSF) in PGF, we retrospectively analyzed 81 episodes of PGF in 66 patients transplanted from 01/94 to 01/99 from an HLA-identical sibling ( n = 45) or an unrelated ( n = 21) donor. Median age was 29 years, 55 patients had malignancies. A total of 11 patients received a CD34+ selected graft. Viral infections (25%), myelotoxic drug (33%), fungal/bacterial infections (14%), and GVHD (31%) were present before PGF diagnosis. Median time from allo-HSCT to PGF was 75 ( 25 - 474) days. All patients were treated with G-CSF. In 77/81 episodes, there was a response that was sustained in 57. A total of 27 patients presented an increase of white cell count (WBC) >0.1 x 10(9)/l after 3 days of G-CSF. The 5-year survival was 37% and was significantly better in patients with increased WBC >0.1 x 10(9)/l after 3 days of G-CSF ( 65 vs 18%, P<0.0001). In multivariate analysis, increased WBC >0.1 x 10(9)/l after 3 days of G-CSF (P = 0.002) was associated with better survival, while BuCy-based conditioning ( P = 0.02) and GVHD ( P = 0.005) were associated with higher risk of death. In conclusion, hematological response after 3 days with G-CSF predicted a better survival for patients with PGF after allo-SCT.
引用
收藏
页码:431 / 435
页数:5
相关论文
共 21 条
[1]  
ASH RC, 1991, BONE MARROW TRANSPL, V7, P443
[2]   Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation [J].
Bittencourt, H ;
Rocha, V ;
Chevret, S ;
Socié, G ;
Espérou, H ;
Devergie, A ;
Dal Cortivo, L ;
Marolleau, JP ;
Garnier, F ;
Ribaud, P ;
Gluckman, E .
BLOOD, 2002, 99 (08) :2726-2733
[3]   Secondary failure of platelet recovery after hematopoietic stem cell transplantation [J].
Bruno, B ;
Gooley, T ;
Sullivan, KM ;
Davis, C ;
Bensinger, WI ;
Storb, R ;
Nash, RA .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (03) :154-162
[4]  
GEORGES G, 2000, CLIN BONE MARROW BLO, P662
[5]   Outcome of cord-blood transplantation from related and unrelated donors [J].
Gluckman, E ;
Rocha, V ;
BoyerChammard, A ;
Locatelli, F ;
Arcese, W ;
Pasquini, R ;
Ortega, J ;
Souillet, G ;
Ferreira, E ;
Laporte, JP ;
Fernandez, M ;
Chastang, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) :373-381
[6]   CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304
[7]  
GREENBERGER JS, 1991, EXP HEMATOL, V19, P1101
[8]  
MCCANN SR, 1994, BONE MARROW TRANSPL, V13, P233
[9]  
NEMUNAITIS J, 1990, BLOOD, V76, P245
[10]   IMPROVEMENT IN REJECTION, ENGRAFTMENT RATE AND SURVIVAL WITHOUT INCREASE IN GRAFT-VERSUS-HOST DISEASE BY HIGH MARROW CELL DOSE IN PATIENTS TRANSPLANTED FOR APLASTIC-ANEMIA [J].
NIEDERWIESER, D ;
PEPE, M ;
STORB, R ;
LOUGHRAN, TP ;
LONGTON, G .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 69 (01) :23-28